Profiles

Keywords
Last Name
Institution

Nancy Reau

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Digestive Diseases and Nutrition
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 15756529900.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, Sarkar S, Golin CE, Reeve BB, Nelson DR, Reau N, Lim JK, Reddy KR, Di Bisceglie AM, Fried MW. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018; 13(8):e0196908. PMID: 30067745.
      View in: PubMed
    2. Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 Oct; 68(4):1298-1307. PMID: 29672891.
      View in: PubMed
    3. Reau N. Pregnancy after liver transplantation: Can renal function quell the fear? Liver Transpl. 2018 05; 24(5):583-584. PMID: 29626391.
      View in: PubMed
    4. VanWagner LB, Reau N. Clinical Liver Disease: Introducing hot topics in hepatology. Clin Liver Dis (Hoboken). 2018 Feb; 11(2):33-34. PMID: 30147866.
      View in: PubMed
    5. Evon DM, Amador J, Stewart P, Reeve BB, Lok AS, Sterling RK, Di Bisceglie AM, Reau N, Serper M, Sarkar S, Lim JK, Golin CE, Fried MW. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1001-1011. PMID: 29377191.
      View in: PubMed
    6. Soriano V, Young B, Reau N. Report from the International Conference on Viral Hepatitis - 2017. AIDS Rev. 2018 Jan-Mar; 20(1):58-70. PMID: 29369303.
      View in: PubMed
    7. Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 May; 68(5):895-903. PMID: 29221887.
      View in: PubMed
    8. Reau N, Robertson MN, Feng HP, Caro L, Yeh WW, Nguyen BT, Wahl J, Barr E, Hwang P, Klopfer SO. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. Hepatol Commun. 2017 10; 1(8):757-764. PMID: 29404492.
      View in: PubMed
    9. Reau N, Nelson DR. HBV reactivation after HCV eradication: Deja Vu. Liver Int. 2017 07; 37(7):1088. PMID: 28635166.
      View in: PubMed
    10. Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS. Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy. Hepatol Commun. 2017 07; 1(5):439-452. PMID: 29404471.
      View in: PubMed
    11. Kanwal F, Bacon BR, Beste LA, Brill JV, Gifford AL, Gordon SC, Horberg MA, Manthey JG, Reau N, Rustgi VK, Younossi ZM. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598. PMID: 28442121.
      View in: PubMed
    12. Behara R, Reau N. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119. PMID: 28350558.
      View in: PubMed
    13. Evon DM, Golin CE, Stewart P, Fried MW, Alston S, Reeve B, Lok AS, Sterling RK, Lim JK, Reau N, Sarkar S, Nelson DR, Reddy KR, Di Bisceglie AM. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials. 2017 06; 57:58-68. PMID: 28342989.
      View in: PubMed
    14. Tran TT, Ahn J, Reau NS. Corrigendum: ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 11; 111(11):1668. PMID: 27808138.
      View in: PubMed
    15. Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 12; 64(6):2210-2218. PMID: 27506929.
      View in: PubMed
    16. Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1. PMID: 27486034.
      View in: PubMed
    17. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048. PMID: 27444413.
      View in: PubMed
    18. Jensen DM, Sebhatu P, Reau NS. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8. PMID: 27306302.
      View in: PubMed
    19. Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Vila RP, Liu L, Pedrosa M, Moller J, Reau N. Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 07; 111(7):1077. PMID: 27356843.
      View in: PubMed
    20. Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS, Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30. PMID: 26642977.
      View in: PubMed
    21. Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Planas Vila R, Liu L, Pedrosa M, Moller J, Reau N. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51. PMID: 27045929.
      View in: PubMed
    22. Desai AP, Reau N. The Burden of Rehospitalization for Patients With Liver Cirrhosis. Hosp Pract (1995). 2016; 44(1):60-9. PMID: 26782133.
      View in: PubMed
    23. Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 Feb; 111(2):176-94; quiz 196. PMID: 26832651.
      View in: PubMed
    24. Reau N, Fried MW, Nelson DR, Brown RS, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502. PMID: 26509462.
      View in: PubMed
    25. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17. PMID: 26575258.
      View in: PubMed
    26. Teriaky A, Reau N. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v. PMID: 26466649.
      View in: PubMed
    27. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44. PMID: 25942724.
      View in: PubMed
    28. Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med. 2015; 7:11-20. PMID: 25926761; PMCID: PMC4403691.
    29. Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H. Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5. PMID: 25742912.
      View in: PubMed
    30. Desai AP, Satoskar R, Appannagari A, Reddy KG, Te HS, Reau N, Meltzer DO, Jensen D. Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol. 2014 Apr; 48(4):e30-6. PMID: 24100752.
      View in: PubMed
    31. Aronsohn A, Reau N, Jensen D. Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology. 2014 May; 59(5):1688-91. PMID: 24806752.
      View in: PubMed
    32. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9. PMID: 24493069.
      View in: PubMed
    33. Reau N. Finding the needle in the haystack: predicting mortality in pregnancy-related liver disease. Clin Gastroenterol Hepatol. 2014 Jan; 12(1):114-6. PMID: 23962550.
      View in: PubMed
    34. Satoskar R, Reau N. Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology. 2013 Jul; 58(1):422-7. PMID: 23460345.
      View in: PubMed
    35. Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013 Jan; 15(1):305. PMID: 23269576.
      View in: PubMed
    36. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat. 2012; 2012:138302. PMID: 23094146; PMCID: PMC3472509.
    37. Desai AP, Reau N, Reddy KG, Te HS, Mohanty S, Satoskar R, Devoss A, Jensen D. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. Therap Adv Gastroenterol. 2012 Sep; 5(5):275-83. PMID: 22973414; PMCID: PMC3437533.
    38. Mufti AR, Reau N. A pregnant patient with a positive hepatitis B surface antigen. Frontline Gastroenterol. 2013 Jan; 4(1):12-19. PMID: 28839696.
      View in: PubMed
    39. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N, Millis JM, Jensen DM. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32. PMID: 22554357.
      View in: PubMed
    40. Mufti AR, Reau N. Liver disease in pregnancy. Clin Liver Dis. 2012 May; 16(2):247-69. PMID: 22541697.
      View in: PubMed
    41. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82. PMID: 22314423.
      View in: PubMed
    42. Desai AP, Reau N. Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis. 2011 Aug; 15(3):483-95. PMID: 21867932.
      View in: PubMed
    43. Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102. PMID: 22239499; PMCID: PMC3489051.
    44. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8. PMID: 21063395.
      View in: PubMed
    45. Aronsohn A, Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009 Aug; 43(7):661-71. PMID: 19448563.
      View in: PubMed
    46. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8. PMID: 18796095; PMCID: PMC2752675.
    47. Singh NA, Reau N. Management of hepatitis B virus. J Antimicrob Chemother. 2008 Aug; 62(2):224-8. PMID: 18480168.
      View in: PubMed
    48. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008 Feb; 12(1):203-17, x. PMID: 18242505.
      View in: PubMed
    49. Sauk J, Jensen DM, Mohanty SR, Reau N, Reddy KG, Te HS. Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis. Gastroenterol Hepatol (N Y). 2006 Jul; 2(7):504-508. PMID: 28289353.
      View in: PubMed
    Reau's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description